ArticleTranslational andrology and urology2025
Migrasome-related long non-coding RNAs orchestrate immune microenvironment and serve as a novel prognostic model in clear cell renal cell carcinoma.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) represents the most common histological subtype of kidney cancer and constitutes a major global health burden. Despite increasing recognition of the roles of migrasome-related long non-coding RNAs (MRLs) in tumor biology, their prognostic relevance in ccRCC remains largely undefined. Therefore, this study aimed to systematically identify MRLs associated with ccRCC prognosis and construct a robust prognostic model to improve risk stratification and guide potential therapeutic strategies. Methods: To identify MRLs, we initially performed a correlation analysis integrating transcriptomic profiles with clinical parameters of ccRCC patients from The Cancer Genome Atlas (TCGA). Leveraging the expression matrix of MRLs, we subsequently employed the least absolute shrinkage and selection operator (LASSO) regression to construct a prognostic signature. A comprehensive assessment was carried out to determine the model's predictive robustness. At single-cell resolution, we delineated the cellular composition of ccRCC, capturing transcriptional heterogeneity across distinct cell populations. Ultimately, long non-coding RNAs (lncRNAs) derived from the prognostic model were experimentally validated in clinical specimens through reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and the landscape of migrasome-related genes (MRGs) was further defined using single-cell RNA sequencing (scRNA-seq) data. Results: A prognostic signature comprising five MRLs-EMX2OS, AC106897.1, AC087645.2, AC121338.2, and C5orf66-was established to stratify patient risk. The derived risk score was subsequently validated as an independent predictor of overall survival (OS) in ccRCC patients. A nomogram integrating this score exhibited strong predictive capability. Immune landscape analysis uncovered marked differences in functional immune features between high- and low-risk cohorts defined by the lncRNA-based model. Notably, the high-risk group displayed enrichment of immune-related processes, whereas the low-risk group demonstrated enhanced predicted responsiveness to a spectrum of therapeutic compounds. scRNA-seq identified 17 distinct cellular subpopulations and highlighted the involvement of tumor cell-intrinsic vascular endothelial growth factor (VEGF) signaling in modulating migrasome-associated molecular programs. Conclusions: This study emphasizes the prognostic utility of a signature comprising five MRLs for ccRCC, offering valuable insights for clinical risk stratification and therapeutic decision-making. Additionally, modulation of tumor cell migration and migrasome function via the VEGF signaling pathway offers a mechanistic basis for targeted intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.